{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:04:26Z","timestamp":1759334666389,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jfo.2015.01.011","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T16:42:08Z","timestamp":1432053728000},"page":"573-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Int\u00e9r\u00eat de la tomographie \u00e0 coh\u00e9rence optique r\u00e9alis\u00e9e imm\u00e9diatement avant injection intra-vitr\u00e9enne d\u2019anti-VEGF sur r\u00e9cidive exsudative dans la DMLA"],"prefix":"10.1016","volume":"38","author":[{"given":"L.","family":"Moyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.Y.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pedinielli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-7545","authenticated-orcid":false,"given":"O.","family":"Semoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Lalloum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Souied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2015.01.011_bib0115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jfo.2009.04.009","article-title":"Epidemiology of age-related macular degeneration","volume":"32","author":"Leveziel","year":"2009","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0120","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jfo.2014.06.001","article-title":"Review and expert opinion in age-related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data","volume":"37","author":"Weber","year":"2014","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0125","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00417-014-2764-6","article-title":"Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials","volume":"252","author":"Kodjikian","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0130","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2015.01.011_bib0135","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2015.01.011_bib0140","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0150","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ajo.2008.12.005","article-title":"Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration","volume":"147","author":"Rothenbuehler","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0155","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/bjo.2009.170670","article-title":"Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting","volume":"94","author":"Querques","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0160","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00417-011-1636-6","article-title":"Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome","volume":"249","author":"Gerding","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0165","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","author":"Berg","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.01.011_bib0170","article-title":"Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen","author":"Rayess","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0175","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ajo.2012.05.022","article-title":"Toward personalized medicine for age-related macular degeneration","volume":"154","author":"Souied","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0180","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.01.011_bib0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.01.011_bib0190","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","article-title":"Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study","volume":"118","author":"Holz","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.01.011_bib0195","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2015.01.011_bib0200","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0205","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.01.011_bib0210","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000342159","article-title":"Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration","volume":"229","author":"Coscas","year":"2013","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jfo.2015.01.011_bib0215","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ajo.2014.04.025","article-title":"Gray hyper-reflective subretinal exudative lesions in exudative age-related macular degeneration","volume":"158","author":"Ores","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.01.011_bib0110","doi-asserted-by":"crossref","first-page":"e005094","DOI":"10.1136\/bmjopen-2014-005094","article-title":"Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial","volume":"4","author":"Dakin","year":"2014","journal-title":"BMJ Open"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018155121500128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018155121500128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:05:27Z","timestamp":1759259127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S018155121500128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S018155121500128X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2015.01.011","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Int\u00e9r\u00eat de la tomographie \u00e0 coh\u00e9rence optique r\u00e9alis\u00e9e imm\u00e9diatement avant injection intra-vitr\u00e9enne d\u2019anti-VEGF sur r\u00e9cidive exsudative dans la DMLA","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2015.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}